Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 4.1%

Bicycle Therapeutics plc (NASDAQ:BCYC) shares rose 4.1% on Tuesday . The stock traded as high as $24.43 and last traded at $24.37. Approximately 25,511 shares were traded during trading, a decline of 93% from the average daily volume of 368,284 shares. The stock had previously closed at $23.41.

Analyst Ratings Changes

BCYC has been the subject of several research analyst reports. Needham & Company LLC restated a “buy” rating and set a $43.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. HC Wainwright reduced their price target on shares of Bicycle Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, February 21st. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, February 21st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $46.86.

Bicycle Therapeutics Price Performance

The stock’s fifty day moving average price is $23.98 and its 200-day moving average price is $19.35. The firm has a market cap of $718.86 million, a price-to-earnings ratio of -4.75 and a beta of 0.89. The company has a current ratio of 8.08, a quick ratio of 8.08 and a debt-to-equity ratio of 0.08.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Tuesday, February 20th. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.07. The firm had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $11.68 million. Bicycle Therapeutics had a negative net margin of 669.72% and a negative return on equity of 57.80%. As a group, equities research analysts forecast that Bicycle Therapeutics plc will post -5.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kevin Lee sold 3,158 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total transaction of $75,191.98. Following the completion of the transaction, the chief executive officer now owns 387,270 shares of the company’s stock, valued at approximately $9,220,898.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 5,312 shares of company stock valued at $126,139. Company insiders own 10.20% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Woodstock Corp boosted its position in Bicycle Therapeutics by 4.5% in the 4th quarter. Woodstock Corp now owns 21,479 shares of the company’s stock valued at $388,000 after buying an additional 926 shares during the period. BluePath Capital Management LLC acquired a new stake in shares of Bicycle Therapeutics in the 3rd quarter valued at $31,000. Exchange Traded Concepts LLC raised its holdings in shares of Bicycle Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock valued at $122,000 after purchasing an additional 1,706 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Bicycle Therapeutics by 71.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,859 shares of the company’s stock valued at $171,000 after purchasing an additional 2,858 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its holdings in shares of Bicycle Therapeutics by 15.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 24,210 shares of the company’s stock valued at $486,000 after purchasing an additional 3,165 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.